Epithalon and Telomerase: What the Research Shows
PeptaBase Research Review | 2026-01-26
What Epithalon Is
Epithalon (also Epitalon) is a 4-amino-acid peptide (AEDG) developed by Vladimir Khavinson at the St. Petersburg Institute of Bioregulation and Gerontology. It's derived from Epithalamin, a natural extract from the pineal gland.
Being tiny-just 4 amino acids-Epithalon can theoretically interact with DNA and turn genes on or off, which is the core hypothesis of Khavinson's program.
Telomerase Activation Research
Epithalon is famous for one claim: it activates telomerase. Here's the background:
Telomeres are chromosome caps that shrink each cell division. Telomerase rebuilds them. Most cells don't have telomerase, which leads to aging.
Khavinson's group published studies (mostly cell culture and animal models) showing Epithalon boosts telomerase activity. Cells treated with Epithalon showed longer telomeres and lived longer in culture.
But here's the catch: independent labs haven't replicated this. And we still don't know how a 4-amino-acid peptide would turn on telomerase machinery. The claim is intriguing but unproven.
Pineal Gland & Melatonin
Epithalon comes from the pineal gland, which makes melatonin and controls sleep-wake cycles. Melatonin drops with age.
Khavinson's animal studies show Epithalon restores melatonin rhythms in old rats, reduces oxidative stress, and lowers cancer rates. Whether this happens through telomerase activation, direct melatonin effects, or something else is unclear.
Khavinson's Research Program
Khavinson's group at St. Petersburg did almost all the Epithalon research over decades. They've published about dozens of bioregulator peptides in Russian-language or low-impact journals.
The results are always positive. But Western researchers haven't replicated this work, and the studies haven't been in major journals. That's a red flag for independent validation.
Administration in Research Protocols
Studies use subcutaneous and intranasal injection. Typical cycles are daily for 10-20 days, sometimes repeated yearly.
Protocols come from this Russian research but are purely experimental. There's no standard dosing because Epithalon hasn't gone through FDA or European drug approval.
Current Evidence Context
Epithalon is a weird case: lots of published research from one lab, intriguing ideas, but almost no independent verification. The telomerase claim especially needs scrutiny-when someone claims they're extending human lifespan, the evidence has to be rock-solid.
Be skeptical. The research is interesting, but it's preliminary.
--- For research use only. Not medical advice.